The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating | S&P Global Ratings

Name: The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating
Uploaded: 2019-08-02T14:39:04.000Z
Duration: T8M44S
Description: The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.

In This List

The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

COMMENTS

Global Auto Outlook: From Drive To Dive

COMMENTS

Global Tariff Tracker: Rating Actions As Of May 2, 2025

COMMENTS

Tadawul On The Rise: Saudi Arabia's Investment Plans Fuel Growth

COMMENTS

U.S. Renewable Power Sector Update: Solar Developers Shine On Through Hazy China

1 Aug, 2019 | 12:00

Listen: The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

Author Arthur Wong
Sector Healthcare & Pharmaceuticals

The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.

Create a free account to unlock the article.

Gain access to exclusive research, events and more.

Already have an account? Sign in